Lahiri, Debomoy K.

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNeuroprotection in Cerebral Ischemia

Cited by 589

An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript

Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry

Iron Metabolism and DisordersRNA and protein synthesis mechanisms

Cited by 551

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 347

Epigenetics, oxidative stress, and Alzheimer disease

Zawia, N. H., Lahiri, D. K., & Cardozo-Pelaez, F. (2009) · Free Radical Biology and Medicine

Alzheimer's disease research and treatmentsEpigenetics and DNA Methylation

Cited by 337

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 331

MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients

Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry

Alzheimer's disease research and treatmentsMicroRNA in disease regulation

Cited by 198

MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects

Long, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry

Alzheimer's disease research and treatmentsMicroRNA in disease regulation

Cited by 187

Neuroprotective and Neurorescue Effects of a Novel Polymeric Nanoparticle Formulation of Curcumin (NanoCurc™) in the Neuronal Cell Culture and Animal Model: Implications for Alzheimer's disease

Ray, B., Bisht, S., Maitra, A., Maitra, A., & Lahiri, D. K. (2011) · Journal of Alzheimer s Disease

Curcumin's Biomedical ApplicationsAlzheimer's disease research and treatments

Cited by 177

Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis

Srinivasan, M., & Lahiri, D. K. (2015) · Expert Opinion on Therapeutic Targets

NF-κB Signaling PathwaysNeuroinflammation and Neurodegeneration Mechanisms

Cited by 164

Autism, Alzheimer disease, and fragile X

Sokol, D. K., Maloney, B., Long, J. M., Ray, B., & Lahiri, D. K. (2011) · Neurology

Genetics and Neurodevelopmental DisordersAlzheimer's disease research and treatments

Cited by 141

Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: Implications in Alzheimer’s disease

Long, J. M., Maloney, B., Rogers, J. T., & Lahiri, D. K. (2019) · Molecular Psychiatry

Alzheimer's disease research and treatmentsMicroRNA in disease regulation

Cited by 141

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?

Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 102

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease

Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 91

Role of cytokines in the gene expression of amyloid β–protein precursor: Identification of a 5'-UTR-Binding nuclear factor and its implications in Alzheimer's disease

Lahiri, D. K., Chen, D., Vivien, D., Ge, Y.-W., Greig, N. H., & Rogers, J. T. (2003) · Journal of Alzheimer s Disease

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 81

Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer’s disease

Maloney, B., Ge, Y., Alley, G. M., & Lahiri, D. K. (2007) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 63

Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease

Kumar, S., Orlov, E., Gowda, P., Bose, C., Swerdlow, R. H., Lahiri, D. K., & Reddy, P. H. (2022) · npj Genomic Medicine

MicroRNA in disease regulationAlzheimer's disease research and treatments

Cited by 46

Interactions between Melatonin, Reactive Oxygen Species, and Nitric Oxide

LAHIRI, D. K., & GHOSH, C. (1999) · Annals of the New York Academy of Sciences

Circadian rhythm and melatoninNeuroprotection in Cerebral Ischemia

Cited by 29